Pharma Veterans

Underground AI in Workplace – Asrar Qureshi’s Blog Post #1145 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1145 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com . Please email to pharmaveterans2017@gmail.com   for publishing your contributions here. Mikhail Nilov Mikhail Nilov Preamble This blog post takes key insights from HR Dive’s article “Younger employees use AI at work but don’t want to tell their bosses”, and couple of other articles on the same subject. It reflects workplace trends, underlying anxieties, and steps managers can take to bring clarity and trust in AI adoption. When AI Goes Underground: What It Means When Employees Don’t Tell Their Bosses In workplaces across the U.S., a surprising trend has taken root: many younger employees are secretly using AI tools at work and deliberately keeping it under wraps. According to a recent HR Dive report, nearly half of Generation Z and millennial ...

Colossal Wrongdoings by Big Pharma – Servier – Asrar Qureshi’s Blog Post #1094 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1094 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Andres Ayrton Credit: Annushka Ahuja Credit: Artem Podrez Preamble For decades, benfluorex – sold under the brand name ‘Mediator’, was marketed as a diabetes and weight-loss drug by French pharmaceutical giant Servier Laboratories. Hailed as a useful tool to help overweight patients manage their health, Mediator was widely prescribed in France and a few other countries from the mid-1970s until 2009. But beneath its therapeutic promise lurked a dangerous reality: the drug was linked to serious, and often fatal, heart valve problems and pulmonary hypertension. By the time it was pulled off the market, Mediator was estimated to have caus...